Personal model-assisted identification of NAD(+) and glutathione metabolism as intervention target in NAFLD
Journal article, 2017

To elucidate the molecular mechanisms underlying non-alcoholic fatty liver disease (NAFLD), we recruited 86 subjects with varying degrees of hepatic steatosis (HS). We obtained experimental data on lipoprotein fluxes and used these individual measurements as personalized constraints of a hepatocyte genome-scale metabolic model to investigate metabolic differences in liver, taking into account its interactions with other tissues. Our systems level analysis predicted an altered demand for NAD(+) and glutathione (GSH) in subjects with high HS. Our analysis and metabolomic measurements showed that plasma levels of glycine, serine, and associated metabolites are negatively correlated with HS, suggesting that these GSH metabolism precursors might be limiting. Quantification of the hepatic expression levels of the associated enzymes further pointed to altered de novo GSH synthesis. To assess the effect of GSH and NAD(+) repletion on the development of NAFLD, we added precursors for GSH and NAD(+) biosynthesis to the Western diet and demonstrated that supplementation prevents HS in mice. In a proof-of-concept human study, we found improved liver function and decreased HS after supplementation with serine (a precursor to glycine) and hereby propose a strategy for NAFLD treatment.

genome-scale

personalized genome-scale metabolic modeling

drug targets

insulin-resistance

serine

adipose-tissue

NAFLD

obesity

glutathione

amino-acid-metabolism

fatty liver-disease

tissue blood-flow

hepatocellular-carcinoma

muscle

Author

Adil Mardinoglu

Chalmers, Biology and Biological Engineering, Systems and Synthetic Biology

Elias Björnson

Chalmers, Biology and Biological Engineering, Systems and Synthetic Biology

C. Zhang

The Royal Institute of Technology (KTH)

M. Klevstig

Sahlgrenska Universitetssjukhuset

S. Soderlund

Helsinki University Central Hospital

Marcus Ståhlman

Sahlgrenska Universitetssjukhuset

Martin Adiels

Sahlgrenska Universitetssjukhuset

A. Hakkarainen

Helsinki University Central Hospital

N. Lundbom

Helsinki University Central Hospital

M. Kilicarslan

Academic Medical Centre, University of Amsterdam

B. M. Hallstrom

The Royal Institute of Technology (KTH)

J. Lundbom

Helsinki University Central Hospital

B. Verges

Centre Hospitalier Universitaire de Dijon

P. H. R. Barrett

University of Western Australia

G. F. Watts

University of Western Australia Faculty of Medicine and Dentistry

M. J. Serlie

Academic Medical Centre, University of Amsterdam

Jens B Nielsen

Chalmers, Biology and Biological Engineering, Systems and Synthetic Biology

M. Uhlen

The Royal Institute of Technology (KTH)

U. Smith

Sahlgrenska Universitetssjukhuset

H. U. Marschall

Sahlgrenska Universitetssjukhuset

M. R. Taskinen

Helsinki University Central Hospital

Jan Borén

Sahlgrenska Universitetssjukhuset

Molecular Systems Biology

1744-4292 (ISSN)

Vol. 13 3 916

Subject Categories (SSIF 2011)

Pharmaceutical Sciences

Biomedical Laboratory Science/Technology

Pharmacology and Toxicology

DOI

10.15252/msb.20167422

More information

Created

10/7/2017